RNA

RNA has transitioned from a speculative biotech into a 'Special Situation' arbitrage play following the definitive $12B acquisition agreement by Novartis at $72.00/share (announced Oct 2025). The current price of $72.87 reflects the $72 cash floor plus the implied market value of the 'SpinCo' (Atrium Therapeutics) containing the cardiology assets, which will be spun off to shareholders prior to the H1 2026 close. The 'Quiet Storm' and 'Alpha Male' signals confirm that the stock is effectively pinned to deal terms, acting as a defensive 'Quality' hold in the current 'Caution' macro regime where investors prefer contractually secured returns over open-market beta.